U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187804) titled 'Long Term Efficacy of Faricimab Using a Treat and Extend Regimen for Type 3 Macular Neovascularization' on Sept. 13.
Brief Summary: Type 3 macular neovascularization (MNV) is a subtype of neovascular age-related macular degeneration accounting for 10-20% of cases, notable for high rates of bilateral involvement and risk of profound vision loss, particularly if undertreated. Early and proactive therapy is crucial to prevent progression and preserve vision.
Faricimab offers potential advantages in this setting. Eyes with type 3 MNV often show thin choroid, reticular pseudodrusen, and high GA risk, reflecting compromised choroidal pe...